5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.62▲ | 1.62▲ | 1.62▼ | 1.59▲ | 1.52▲ |
MA10 | 1.62▼ | 1.62▼ | 1.66▼ | 1.53▲ | 1.41▲ |
MA20 | 1.62▲ | 1.66▼ | 1.66▼ | 1.51▲ | 1.33▲ |
MA50 | 1.64▼ | 1.63▼ | 1.56▲ | 1.38▲ | 2.74▼ |
MA100 | 1.67▼ | 1.55▲ | 1.51▲ | 1.35▲ | 4.33▼ |
MA200 | 1.65▼ | 1.51▲ | 1.50▲ | 2.29▼ | 8.09▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | -0.009▼ | -0.015▼ | 0.012▲ | 0.153▲ |
RSI | 46.719▼ | 42.625▼ | 49.764▼ | 57.212▲ | 45.909▼ |
STOCH | 18.333▼ | 12.540▼ | 8.333▼ | 75.602 | 78.132 |
WILL %R | -66.667 | -91.667▼ | -92.308▼ | -33.333 | -15.429▲ |
CCI | -50.231 | -65.893 | -89.800 | 140.636▲ | 109.715▲ |
Friday, June 13, 2025 01:05 PM
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...
|
Sunday, May 11, 2025 01:30 AM
Alector, Inc. (NASDAQ:ALEC) shareholders are probably feeling a little disappointed, since its shares fell 10.0% to US$1.17 in the week after its latest first-quarter results.
|
Wednesday, February 26, 2025 02:55 PM
Alector (ALEC) delivered earnings and revenue surprises of 96.88% and 220.64%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
11/07/25 | 1.69 | 1.705 | 1.60 | 1.61 | 254,301 |
10/07/25 | 1.64 | 1.745 | 1.62 | 1.72 | 711,080 |
09/07/25 | 1.52 | 1.69 | 1.51 | 1.65 | 565,502 |
08/07/25 | 1.45 | 1.56 | 1.45 | 1.52 | 455,325 |
07/07/25 | 1.49 | 1.49 | 1.41 | 1.44 | 306,500 |
03/07/25 | 1.50 | 1.51 | 1.44 | 1.51 | 233,289 |
02/07/25 | 1.43 | 1.56 | 1.42 | 1.50 | 422,549 |
01/07/25 | 1.38 | 1.51 | 1.34 | 1.42 | 439,740 |
30/06/25 | 1.49 | 1.49 | 1.365 | 1.40 | 679,974 |
27/06/25 | 1.51 | 1.51 | 1.44 | 1.48 | 2,122,416 |
|
|
||||
|
|
||||
|
|